CELLID, CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,765 KRW | 0.00% |
|
-0.79% | -15.77% |
| 2023 | Cellid, Co., Ltd.(KOSDAQ:A299660) dropped from S&P Global BMI Index | CI |
| 2021 | Private S.Korea firms plan $5.4 billion investment to create vaccine hub | RE |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 262,935 | 394,737 | 477,802 | 114,342 | 60,805 |
| Enterprise Value (EV) 1 | 236,542 | 382,720 | 473,510 | 107,584 | 57,387 |
| P/E ratio | -103 x | -95.1 x | -36.5 x | -5 x | -4.15 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | 525,581,679 x | 238,211,476 x | - |
| EV / Revenue | - | - | 520,860,841 x | 224,134,002 x | - |
| EV / EBITDA | -69.1 x | -79.8 x | -44.2 x | -8.74 x | -6.02 x |
| EV / FCF | -40.1 x | -25.8 x | -57.4 x | -30.9 x | -2.89 x |
| FCF Yield | -2.49% | -3.88% | -1.74% | -3.24% | -34.6% |
| Price to Book | 5.12 x | 8.35 x | 12.3 x | 5.1 x | 1.5 x |
| Nbr of stocks (in thousands) | 9,579 | 9,699 | 9,731 | 9,731 | 13,603 |
| Reference price 2 | 27,450 | 40,700 | 49,100 | 11,750 | 4,470 |
| Announcement Date | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | 909.1 | 480 | - |
| EBITDA 1 | -2,298 | -3,421 | -4,795 | -10,723 | -12,311 | -9,534 |
| EBIT 1 | -2,375 | -3,531 | -5,287 | -13,011 | -14,911 | -12,198 |
| Operating Margin | - | - | - | -1,431.2% | -3,106.53% | - |
| Earnings before Tax (EBT) 1 | -11,286 | -2,494 | -4,126 | -13,071 | -22,865 | -11,611 |
| Net income 1 | -11,286 | -2,494 | -4,126 | -13,071 | -22,865 | -11,611 |
| Net margin | - | - | - | -1,437.76% | -4,763.45% | - |
| EPS 2 | -1,424 | -265.7 | -427.9 | -1,346 | -2,350 | -1,078 |
| Free Cash Flow 1 | -11,116 | -5,893 | -14,832 | -8,255 | -3,485 | -19,854 |
| FCF margin | - | - | - | -908.07% | -726.13% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/1/19 | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 7,885 | 26,394 | 12,017 | 4,292 | 6,757 | 3,418 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -11,116 | -5,893 | -14,832 | -8,255 | -3,485 | -19,854 |
| ROE (net income / shareholders' equity) | -283% | -7.69% | -8.37% | -30.4% | -74.7% | -36.9% |
| ROA (Net income/ Total Assets) | -15.5% | -6.61% | -6.48% | -15.1% | -17.9% | -13.9% |
| Assets 1 | 72,923 | 37,703 | 63,634 | 86,520 | 127,716 | 83,601 |
| Book Value Per Share 2 | 1,574 | 5,359 | 4,877 | 3,983 | 2,306 | 2,977 |
| Cash Flow per Share 2 | 103.0 | 175.0 | 358.0 | 535.0 | 848.0 | 984.0 |
| Capex 1 | 5,817 | 4,284 | 11,715 | 3,112 | 1,203 | 6,922 |
| Capex / Sales | - | - | - | 342.29% | 250.61% | - |
| Announcement Date | 3/1/19 | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -15.77% | 38.02M | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- A299660 Stock
- Financials Cellid, Co., Ltd.
